Repetitive Transcranial Magnetic Stimulation (rTMS) of spinal cord for freezing of gait in Parkinson’s disease: A Pilot Study

threshold, over the left dorsolateral prefrontal cortex. We compared remission and response rates with different comorbidities using ChiSquare analyses. Results: Of 77 patients (71.4% female, mean age 48.9 years), 10 had GAD,18 had PDD, and 7 had BPD. Mean (+SD) TMS treatments was 31 (7.2). Overall remission was 20.8% and response was 36.4%. There was no significant difference between these rates in patients with vs without GAD (remission p1⁄40.9, response p1⁄40.9), PDD (remission p1⁄40.8, response p1⁄40.2), and BPD (remission p1⁄40.06, response p1⁄40.5). Conclusion: TMS was equally effective among MDD patients with GAD, PDD, and BPD comorbidities. Patients with these comorbidities can be reassured of efficacy. Conflicts of interest Dr. Croarkin received research grant support from Pfizer ( WS1926243 ), National Institute of Mental Health ( K23MH10026 and R01MH113700 ), the Brain and Behavior Research Foundation ( 20883 ), and the Mayo Clinic Foundation . He has received equipment support from Neuronetics, Inc and receives supplies and genotyping services from Assurex Health, Inc for investigator-initiated studies. He is the primary investigator for a multicenter study of adolescent TMS funded by Neuronetics, Inc. : Drs. Kung receives in-kind support from Neuronetics, Inc, for a TMS and bipolar research study. Other authors have no conflict of interest to disclose. Funding source: None